Generic name |
glatiramer acetate (Glatect™, Mylan-Glatiramer) |
---|---|
Strength & form |
20 mg/mL pre-filled syringe |
Special Authority criteria |
Approval period |
---|---|
InitialAs first-line monotherapy for the treatment of relapsing-remitting multiple sclerosis (MS) diagnosed according to the current clinical criteria and magnetic resonance imaging (MRI) evidence, when prescribed by a neurologist from a designated MS clinic, for patients who meet ALL the following criteria:
AND
|
15 months |
RenewalAs monotherapy, when prescribed by a neurologist from a designated MS clinic, for the treatment of patients with relapsing-remitting MS who have demonstrated that the therapeutic benefits outweigh any potential risks, as shown by relapse rate, EDSS, MRI scan, or overall clinical impression. |
24 months |
Change of therapyAs monotherapy, when prescribed by a neurologist from a designated MS clinic, for the treatment of patients with relapsing-remitting MS who have experienced failure or intolerance to a previous disease modifying therapy. |
15 months |